Campylobacterantimicrobial resistance in Peru: a ten-year observational study

BMC Infectious Diseases

Research Article

Drake Tilley¹  Claudio Rocha¹  Juan Perez¹  Rina Meza¹  Simon Pollett¹  Franca Jones¹  Marieke Rosenbaum¹  Ryan Maves¹  Matthew Kasper¹  Michael Gregory¹  Eric Hall¹  Maruja Bernal¹  Nancy Chuquiray²  C Sofia Arriola³  Carlos Calampa⁴  José Guevara⁵  Augusto Valencia⁶  Martín Casapia⁷  Máximo Camiña⁸  Lilian Patiño⁹  Rito Zerpa⁹  Eduardo Salazar-Lindo^1,10  Martha Lopez^1,11 

[1] Bacteriology Department, U.S Naval Medical Research Unit-6 (NAMRU-6), Venezuela Ave, Block 36, Callao 2, Lima, Peru;EsSalud Hospital Alberto Sabogal Sologuren, Lima, Peru;Facultad de Medicina Veterinaria, Universidad de San Marcos, San Marcos, Peru;Hospital Apoyo de Iquitos, Iquitos, Peru;Hospital Nacional Daniel A.Carrion, Lima, Peru;Hospital Nacional Docente Madre-Niño, Lima, Peru;Hospital Regional, Iquitos, Peru;Hospital de Emergencias Pediátricas, Lima, Peru;Instituto Nacional de Salud del Niño, Lima, Peru;Laboratorio Gastrolab, Lima, Peru;Laboratorio Servisalud, Cusco, Peru;

关键词: Campylobacter;    Antibiotic resistance;    Fluoroquinolones;    Macrolides;    Peru;   

DOI  :  10.1186/1471-2334-12-193

 received in 2011-12-20, accepted in 2012-06-19,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundCampylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers’ diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.MethodsSurveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).ResultsComparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).ConclusionsThese results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

【 授权许可】

CC BY   
© Pollett et al.; licensee BioMed Central Ltd. 2012